Mindbloom is the first national provider of clinician‑guided, at‑home ketamine therapy for anxiety and depression. Despite promising clinical efficacy, early‑stage clients stalled after the first program: only a 12% repurchased, citing confusing onboarding, uncertain dosing, and fragmented digital touchpoints. Retention was the #1 business risk as acquisition costs climbed and funding tightened.